The detection of GPC1+ crExos in the serum of pancreatic cancer patients showed exceptional specificity and sensitivity, allowing for clear differentiation between healthy individuals, patients with benign pancreatic diseases, and those with early and advanced-stage pancreatic cancer. Here, GPC1 is linked to pancreatic neoplasm.